ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 937,90
-0,75%
Dow Jones
38 597,31
0,07%
DAX
18 405,64
-1,10%
Brent Oil
77,645
-0,63%
Bitcoin
70 596,12
2,60%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Biocept Inc (BIOC)

  7. Biocept Inc (BIOC) Actualités

BIOC

Biocept (BIOC)

Biocept Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BIOC
DateHeureSourceTitreSymboleSociété
20/10/202312h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIOCBiocept Inc
21/09/202314h00Business WireEnrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesNASDAQ:BIOCBiocept Inc
08/09/202314h00Business WireBiocept Signs CNSide™ Licensing Agreement with Plus TherapeuticsNASDAQ:BIOCBiocept Inc
05/09/202314h00Business WireBiocept to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:BIOCBiocept Inc
25/08/202314h00Business WireBiocept to Hold Business Update Conference Call on August 30, 2023NASDAQ:BIOCBiocept Inc
14/08/202322h05Business WireBiocept Reports Second Quarter 2023 Financial ResultsNASDAQ:BIOCBiocept Inc
14/08/202314h00Business WireBiocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer ConferenceNASDAQ:BIOCBiocept Inc
14/07/202300h15Business WireBiocept Announces the Passing of Board Chair M. Faye WilsonNASDAQ:BIOCBiocept Inc
21/06/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BIOCBiocept Inc
21/06/202301h10Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BIOCBiocept Inc
20/06/202322h15Business WireBiocept Names Antonino Morales as President and Chief Executive OfficerNASDAQ:BIOCBiocept Inc
14/06/202322h05Business WireBiocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023NASDAQ:BIOCBiocept Inc
05/06/202314h00Business WireScientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus CytologyNASDAQ:BIOCBiocept Inc
25/05/202312h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BIOCBiocept Inc
25/05/202302h39Business WireBiocept Announces Pricing of $5.0 Million Underwritten Public OfferingNASDAQ:BIOCBiocept Inc
23/05/202314h18Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:BIOCBiocept Inc
17/05/202314h00Business WireBiocept Announces One-for-Thirty Reverse Stock SplitNASDAQ:BIOCBiocept Inc
10/05/202322h05Business WireBiocept Reports First Quarter 2023 Financial ResultsNASDAQ:BIOCBiocept Inc
21/04/202314h31Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:BIOCBiocept Inc
20/04/202322h07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BIOCBiocept Inc
17/04/202322h10Business WireBiocept Reports 2022 Financial ResultsNASDAQ:BIOCBiocept Inc
17/04/202322h04Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:BIOCBiocept Inc
03/04/202314h01Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BIOCBiocept Inc
24/03/202313h00Business WireEnrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal MetastasesNASDAQ:BIOCBiocept Inc
01/03/202314h00Business WireBiocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BIOCBiocept Inc
06/01/202312h55Business WireBiocept to Explore Strategic Alternatives and Implement Restructuring PlanNASDAQ:BIOCBiocept Inc
21/11/202222h12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BIOCBiocept Inc
21/11/202222h05Business WireBiocept Reports Third Quarter 2022 Financial ResultsNASDAQ:BIOCBiocept Inc
18/11/202214h00Business WireBiocept Appoints Financial Executive Quyen Dao-Haddock to its Board of DirectorsNASDAQ:BIOCBiocept Inc
16/11/202214h00Business WireBiocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous SystemNASDAQ:BIOCBiocept Inc
 Showing the most relevant articles for your search:NASDAQ:BIOC

Dernières Valeurs Consultées

TSXV
NPTH
Neupath Health
DBI
I9NS
IN XTK 2 TMASE29 CB SF
TSXV
RMK
Red Moon Resources
LSE
BPFQ
Blue Planet Gw&inc I.T.9
NASDAQ
AVHI
Achari Ventures Holdings...
NASDAQ
BIMI
BIMI International Medical
LSE
TRV
Treveria
COIN
HAOUSD
History Dao Token
TSX
PIC.A
Premium Income
AMEX
MGN
Mines
COIN
CAGEGBP
NYSE
USB.PRP
US Bancorp Del
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés